What's Happening?
Bruker Corporation has announced a majority investment in MIMETAS B.V., a company specializing in organ-on-a-chip platforms and human tissue models. This strategic move aims to expand Bruker's capabilities in post-genomic solutions for disease biology
research and drug discovery. MIMETAS' OrganoPlate platform allows for advanced disease modeling and drug testing by providing scalable organ-on-a-chip solutions. These platforms enable researchers to study disease mechanisms and compound responses in biologically relevant systems. Bruker plans to integrate these capabilities with its existing technologies in proteomics, metabolomics, and spatial biology. The collaboration is expected to enhance the development of humanized Microphysiological Systems, which are increasingly important for understanding disease biology and evaluating therapeutic candidates.
Why It's Important?
The investment by Bruker in MIMETAS signifies a significant advancement in the field of drug discovery and development. By leveraging MIMETAS' organ-on-a-chip technology, Bruker aims to provide more accurate human tissue models that can improve the predictability of drug responses. This could lead to more efficient drug development processes and reduce reliance on animal testing. The integration of these technologies is expected to support pharmaceutical and biotechnology researchers in making informed decisions regarding disease research and drug development. The collaboration could also accelerate the adoption of New Approach Methodologies, which are crucial for advancing human-centric research and improving patient outcomes.
What's Next?
Bruker and MIMETAS plan to develop integrated product and service workflows that connect human model systems with Bruker's molecular and cellular characterization technologies. This collaboration is expected to enhance evidence generation for disease research and drug development decisions. MIMETAS will continue to operate under its established brand and management, while Bruker will focus on scaling the platforms to make advanced human tissue models more accessible to researchers worldwide. The financial details of the transaction have not been disclosed.
